GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Operating Margin %

Durata Therapeutics (FRA:DTA) Operating Margin % : -181.17% (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Durata Therapeutics's Operating Income for the three months ended in Sep. 2014 was €-14.17 Mil. Durata Therapeutics's Revenue for the three months ended in Sep. 2014 was €7.82 Mil. Therefore, Durata Therapeutics's Operating Margin % for the quarter that ended in Sep. 2014 was -181.17%.

The historical rank and industry rank for Durata Therapeutics's Operating Margin % or its related term are showing as below:

FRA:DTA' s Operating Margin % Range Over the Past 10 Years
Min: -679.94   Med: 0   Max: 0
Current: -679.94


FRA:DTA's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -171.86 vs FRA:DTA: -679.94

Durata Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Durata Therapeutics's Operating Income for the three months ended in Sep. 2014 was €-14.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2014 was €-50.86 Mil.


Durata Therapeutics Operating Margin % Historical Data

The historical data trend for Durata Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics Operating Margin % Chart

Durata Therapeutics Annual Data
Trend Dec11 Dec12 Dec13
Operating Margin %
- - -

Durata Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -181.17

Competitive Comparison of Durata Therapeutics's Operating Margin %

For the Biotechnology subindustry, Durata Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's Operating Margin % falls into.



Durata Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Durata Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2013 is calculated as

Operating Margin %=Operating Income (A: Dec. 2013 ) / Revenue (A: Dec. 2013 )
=-41.59 / 0
= %

Durata Therapeutics's Operating Margin % for the quarter that ended in Sep. 2014 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2014 ) / Revenue (Q: Sep. 2014 )
=-14.173 / 7.823
=-181.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Durata Therapeutics  (FRA:DTA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Durata Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines